Angiodynamics INC: insider trades · United States · SEC (Form 4)

About Angiodynamics INC

AngioDynamics Inc. (ticker: ANGO) is a U.S.-based medical technology company listed on the NASDAQ in the United States. Founded in 1988 in Queensbury, New York, and later relocating its corporate headquarters to Latham, New York in 2010, the company has developed into a focused specialist in minimally invasive devices used for peripheral vascular disease and selected cancer therapies. Its NASDAQ listing and its positioning in interventional healthcare make it a closely watched name for investors seeking exposure to medtech innovation, clinical adoption, and product-cycle execution. AngioDynamics’ business is organized around a mix of growth-oriented “Med Tech” platforms and a broader “Med Device” portfolio. The Med Tech franchise includes NanoKnife, the company’s irreversible electroporation system used in ablation therapy; Auryon, its peripheral atherectomy platform for peripheral artery disease; and AngioVac and AlphaVac, which are used in mechanical thrombectomy and aspiration-based clot removal. The broader device portfolio also includes vascular access products such as implantable ports and PICCs, angiographic accessories, drainage products, thrombolytic products, and venous solutions. This portfolio breadth gives the company multiple commercial touchpoints, but it also places AngioDynamics in a highly competitive market against larger global medtech peers with greater scale and distribution reach. Geographically, AngioDynamics sells in the United States through a direct sales force, while international sales are handled through a combination of direct channels and distributors. That footprint reflects a company that remains predominantly U.S.-anchored operationally, with headquarters in Latham, New York, but with a broader global commercialization strategy. The company’s competitive edge is built less on commoditized devices and more on differentiated technology, clinical evidence, and incremental regulatory clearances that can expand the use cases for its platforms. Recent developments have reinforced the company’s transformation narrative. In April 2026, AngioDynamics reported fiscal third-quarter 2026 results showing continued double-digit growth in its Med Tech segment and reiterated that the segment has been a key driver of overall performance. The company also raised full-year fiscal 2026 guidance for the third consecutive quarter, while maintaining a debt-free balance sheet and reporting $37.8 million in cash at the end of February 2026. In May 2026, AngioDynamics announced two-year PRESERVE trial data for NanoKnife in intermediate-risk prostate cancer, which is an important clinical update for a core growth asset. For investors, ANGO remains a U.S. NASDAQ-listed medtech company with meaningful upside tied to product adoption, clinical validation, and execution, but it also carries the usual sector risks related to regulation, reimbursement, competition, and manufacturing transitions.